Literature DB >> 9607132

Effects of long-term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure.

P E Vardas1, E M Kanoupakis, G E Kochiadakis, E N Simantirakis, M E Marketou, G I Chlouverakis.   

Abstract

We evaluated the effects of long-term digoxin therapy on exercise capacity and on physiological parameters reflecting autonomic tone in 23 patients with mild to moderate heart failure. Before and after maintenance digoxin treatment, all patients underwent cardiopulmonary exercise testing and indexes of heart rate variability (HRV) and baroreceptor sensitivity (BRS) were measured. Long-term digoxin therapy significantly (P < 0.05) increased time domain indexes (rMSSD, pNN50) which reflect parasympathetic activity (from 30 +/- 16 to 37 +/- 14 and from 8 +/- 9 to 12 +/- 7, respectively). High-frequency (HF) and low-frequency (LF) power spectral components also showed a significant increase (from 4.5 +/- 1 to 5.1 +/- 1 and from 5.4 +/- 1 to 5.8 +/- 1, respectively), but the ratio LF/HF decreased, indicating a predominance of vagal activity. The magnitude of these changes exhibited a strong negative Pearson correlation coefficient when compared with initial values before treatment. BRS increased from 2.95 +/- 1.2 to 5.32 +/- 3 ms/mmHg (P < 0.05). Oxygen consumption at peak exercise and at the anerobic threshold increased significantly (from 17 +/- 3 to 19 +/- 3 mL/kg/min and from 14.7 +/- 3 to 16.5 +/- 3 mL/kg/min, respectively). A persistent negative correlation was found between initial values of HRV and the magnitude of changes in exercise capacity. These findings show that long-term digoxin therapy increases vagal activity and improves exercise capacity in patients with mild to moderate heart failure and seems to exert a more marked therapeutic effect on patients with poorer initial autonomic function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607132     DOI: 10.1023/a:1007785314462

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  6 in total

Review 1.  Pharmacologic modulation of parasympathetic activity in heart failure.

Authors:  Monali Y Desai; Mari A Watanabe; Abhay A Laddu; Paul J Hauptman
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

Review 2.  Baroreflex sensitivity: measurement and clinical implications.

Authors:  Maria Teresa La Rovere; Gian Domenico Pinna; Grzegorz Raczak
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-04       Impact factor: 1.468

3.  Effects of carvedilol on heart rate dynamics in patients with congestive heart failure.

Authors:  Mustafa Ridha; Timo H Mäkikallio; Gustavo Lopera; Juan Pastor; Eduardo de Marchena; Simon Chakko; Heikki V Huikuri; Agustin Castellanos; Robert J Myerburg
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-04       Impact factor: 1.468

4.  Digoxin and mortality in atrial fibrillation: a prospective cohort study.

Authors:  Pär Hallberg; Johan Lindbäck; Bertil Lindahl; Ulf Stenestrand; Håkan Melhus
Journal:  Eur J Clin Pharmacol       Date:  2007-08-08       Impact factor: 2.953

5.  Changes in heart rate variability of depressed patients after electroconvulsive therapy.

Authors:  Erica B Royster; Lisa M Trimble; George Cotsonis; Brian Schmotzer; Amita Manatunga; Natasha N Rushing; Giuseppe Pagnoni; S Freda Auyeung; Angelo R Brown; Joel Schoenbeck; Smitha Murthy; William M McDonald; Dominique L Musselman
Journal:  Cardiovasc Psychiatry Neurol       Date:  2012-08-27

6.  Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis.

Authors:  Ying Chen; Xiaoyan Cai; Weijun Huang; Yanxian Wu; Yuli Huang; Yunzhao Hu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.